GSK
GSK | NYSE
$51.02
+$0.80 (+1.59%)
Sep 21, 2026, 10:26 AM ET · Market open
Market Data
Market Cap $100.62B
Enterprise Value $90.93B
Beta 0.29
Average Volume 3.83M
Shares Outstanding (Diluted) 2.03B
Shares Change YoY -1.17%
Institutional Ownership 18.60%
Exchange NYSE
ISIN US37733W2044
Price Performance
Price Change 1M -2.3%
Price Change 3M -1.0%
Price Change 6M -3.4%
Price Change YTD 1.2%
Price Change 1Y 24.6%
Price Change 3Y 34.2%
Price Change 5Y 30.8%
1M CAGR (ann.) -2.9%
1Y CAGR (ann.) 28.9%
5Y CAGR (ann.) 9.1%
All-Time CAGR 4.7%
Valuation
PE Ratio 13.00
Forward PE 9.48
PEG Ratio 0.37
Forward PEG 2.26
PS Ratio 2.26
Forward PS 2.10
PB Ratio 4.33
P/FCF Ratio 10.74
P/Adj. FCF Ratio 10.74
P/OCF Ratio 9.40
EV/Sales 2.74
EV/EBIT 10.74
EV/EBITDA 8.52
EV/FCF 13.03
Earnings Yield 7.7%
FCF Yield 9.3%
Adj. FCF Yield 9.3%
Financial Health
Net Debt £15.04B
Total Debt £18.13B
Cash & Short-Term Investments £3.09B
Total Assets £61.37B
Current Ratio 0.82
Quick Ratio 0.52
Debt / Equity Ratio 1.03
Debt / EBITDA 1.70
Debt / FCF 2.60
OCF / Debt 0.48
Interest Coverage 11.37
Altman Z-Score 2.21
Piotroski F-Score 8
Margins & Profitability
Gross Profit Margin 73.3%
Operating Profit Margin 26.5%
EBITDA Margin 33.0%
Net Profit Margin 14.5%
FCF Margin 21.0%
Adj. FCF Margin 21.0%
SBC / Revenue 0.0%
SBC Impact (per share) N/A
Returns
Return on Assets 7.8%
Return on Equity 28.4%
Return on Invested Capital 16.0%
Return on Capital Employed 19.9%
Return on Tangible Assets 12.8%
Historical Growth (CAGR)
Revenue CAGR 3Y 4.3%
Revenue CAGR 5Y 1.6%
Revenue CAGR 10Y 2.8%
EPS CAGR 3Y -27.5%
EPS CAGR 5Y 5.5%
EPS CAGR 10Y 62.8%
FCF CAGR 3Y 38.0%
FCF CAGR 5Y 5.8%
FCF CAGR 10Y 16.6%
Analyst Forecasts
Analyst Rating Hold
Analyst Count 29
EPS Growth Next 3Y 13.5%
Revenue Growth Next 3Y 4.9%
Earnings Date N/A
EPS Estimate (next Q) N/A
EPS Growth Est (next Q) N/A
Revenue Est (next Q) N/A
Revenue Growth Est (next Q) N/A
Fair Value Estimates
Graham Number $31.22
Graham Upside -37.8%
Lynch Fair Value $21.37
Lynch Upside -57.5%
Price Target $60
Price Target Upside 19.5%
Cash Flow
Operating Cash Flow £8.74B
Free Cash Flow £6.98B
Adj. Free Cash Flow £6.98B
FCF Per Share $2.87
OCF Per Share $3.98
OCF/S Ratio 24.0%
Income Statement
Revenue £33.25B
Gross Profit £24.35B
Operating Income £8.8B
EBITDA £10.68B
Net Income £4.82B
EPS (Diluted) $2.88
Revenue / Employee $497.4K
Profit / Employee $72.16K
Employees 66,841
Dividends
Annual Dividend $1.82
Dividend Yield 3.62%
Payout Ratio 63.1%
FCF Payout Ratio 41.6%
Adj. FCF Payout Ratio 41.6%
Dividend Growth (YoY) 9.8%
Pay Frequency Quarterly
Ex-Dividend Date Aug 13, 2026
Add to Watchlist
Select watchlists to add or remove GSK